Abstract：Objective To investigate the clinical effect of Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease. Methods A total of 60 patients with heart failure of coronary heart disease admitted to our hospital from January 2015 to January 2018 were selected and divided into the control group and the observation group according to random lottery, 30 cases in each group. Patients in the control group were given routine treatment, while patients in the observation group were given Metoprolol combined with Trimetazidine. The clinical efficacy, left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) and left ventricular end systolic diameter (LVESD) were measured and observed before and after treatment in the two groups. Results The clinical total effective rate in the observation group was 93.33%, which was significantly higher than that in the control group (70.00%), and the difference was statistically significant (P＜0.05). Before treatment, there were no significant differences in LVEDD, LVEF and LVESD between the two groups (P＞0.05). After treatment, the level of LVEF of the observation group was significantly higher than that before treatment and the control group, while the level of LVEDD and LVESD of the observation group were significantly lower than those before treatment and the control group, and the difference was statistically significant (P＜0.05). Conclusion Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease can effectively improve the patient′s heart function, the clinical effect is ideal.
于杰. 美托洛尔联合曲美他嗪治疗冠心病心力衰竭效果分析[J]. 中国当代医药, 2019, 26(9): 67-69.
YU Jie. Analysis of the effect of Metoprolol combined with Trimetazidine in the treatment of heart failure of coronary heart disease. 中国当代医药, 2019, 26(9): 67-69.
京公网安备 11010502046607号